Home> Products> Inhibitors> BEZ235 Tosylate-CAS 1028385-32-1
price inquiry for CAS:1028385-32-1, Product:BEZ235 Tosylate
For research use only. We do not sell to patients.

BEZ235 Tosylate CAS: 1028385-32-1

Category: Inhibitors
Product Name: BEZ235 Tosylate
Cat No: I000176
CAS No: 1028385-32-1
Synonyms: 4-methylbenzenesulfonic acid;2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile
Molecular Formula: C37H31N5O4S
Molecular Weight: 641.74
SMILES: CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5
Solubility: 10 mM in DMSO
Target: PI3K
IC50: 4 nM/5 nM/7 nM/75 nM/6 nM(p110α/γ/δ/β/mTOR) [1]
Storage: Store at -20°C
CAS 1028385-32-1,BEZ235 Tosylate
  • Description

BEZ235 tosylate(NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively; inhibits ATR with IC50 of 21 nM; shown to be poor inhibitory to Akt and PDK1.
IC50 value: 4 nM/5 nM/7 nM/75 nM/6 nM(p110α/γ/δ/β/mTOR) [1]
Target: PI3K/mTOR
in vitro: BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ23 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM [1]. BEZ235 is an mTORC1/2 catalytic inhibitor [2].
in vivo: BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies [1].

  • References

[1]. Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 2008, 7(7), 1851-1863.
[2]. Roper J, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One, 2011, 6(9), e25132.

price inquiry for CAS:1028385-32-1, Product:BEZ235 Tosylate